撰文丨王聪 编辑丨王多鱼 排版丨水成文 最近几十年来，随着塑料制品的广泛使用，环境中的 微塑料/纳米塑料 （MNP） 变得无处不在。更重要的是，越来越多的研究显示，这些微塑料/纳米塑料可以 在人体内积累，科学家们已经在 肺 、 肾脏 、 肝脏 、 生殖系统 ，甚至是 大脑 中发现了 微塑料/纳米塑料的存在。 现实生活中，微塑料/纳米塑料无处不在，我们所呼吸的空气、瓶装水、食品包装袋、外卖盒等等，导致我们不可避免地接触并摄入 微塑料/纳米塑料。 之前的研究显示，微塑料/纳米塑料会破坏肠道菌群平衡，与哺乳动物 肠屏障功能障碍、炎症和免疫失衡相关。实际上，大多数相关研究集中在微塑料上， 但研 究人员推测， 微塑料的毒性会随着粒径的减小而增加，纳米塑料由于其纳米级尺寸 （小于1000纳米） ，可以穿透 组织和器官，可能造成更严重的潜在生物危 害。但纳米塑料、肠道菌群和宿主之间的相互作用仍然是一个谜，它们的潜在机制尚不清楚。 2025 年 6 月 10 日，中国台湾学者在 Nature 子刊 Nature Communications 上发表了题为： Polystyrene nanoplastics disrupt t ...

Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right ("CVR") upon the achievement of a regulatory milestone, for a total equity value of up to approximately $1.7 billion; Expected to be completed in the second half of 2025, subject to customary closing conditionsPositive topline data from the completed fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) study of f ...

Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal diseaseLead asset for ADPKD, farabursen, is a novel, next-generation oligonucleotide targeting miR-17 that recently completed a Phase 1b multiple-ascending dose clinical trial Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a future regulatory milestone; transaction ...

SAN DIEGO, April 2, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, CEO, will participate in a presentation at the 2025 Oppenheimer Innovation on the Island Biotech Summit on Wednesday, April 9th at 11:32 a.m. ET.The live event and replay of the presentation will be available under "Events and Presentations" through the ...

Core Insights - Regulus Therapeutics announced positive topline results from the fourth cohort of its Phase 1b MAD study of farabursen for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD) [2][4] - The study demonstrated a significant halting of kidney volume growth in patients receiving a 300 mg fixed dose of farabursen over four months [1][4] - The company is on track to initiate a Phase 3 pivotal trial in Q3 2025, with a focus on a 12-month endpoint for kidney volume change [2][6] Study Details - The Phase 1b MAD study was a double-blind, placebo-controlled trial assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of farabursen in adult ADPKD patients [3] - The study included three weight-based dose levels and one fixed dose level, with primary endpoints focused on urinary PC1 and PC2 changes, and an exploratory examination of htTKV growth rate [3][4] - In the fourth cohort, 26 subjects received 300 mg of farabursen bi-weekly for three months, showing consistent mechanistic responses and halting htTKV growth [4][5] Efficacy and Safety - Patients treated with farabursen showed a mean htTKV growth rate of 0.05%, compared to 2.58% in placebo subjects, indicating a significant reduction in kidney volume growth [5] - Urinary levels of PC1 and PC2 increased significantly, correlating with the observed effects on kidney volume [5] - Farabursen demonstrated a favorable safety and tolerability profile, consistent with earlier cohorts, with no serious adverse events reported [5][9] Future Plans - The company has confirmed alignment with the FDA regarding the Phase 3 trial design, which includes a 12-month htTKV endpoint for Accelerated Approval and a 24-month eGFR endpoint for Full Approval [6][9] - Regulus aims to advance farabursen as a potential treatment option for ADPKD, addressing a significant unmet medical need [6][10] Background on ADPKD - ADPKD is a common genetic disorder characterized by the development of multiple cysts in the kidneys, leading to end-stage renal disease in approximately 50% of patients by age 60 [8] - The disease affects around 160,000 individuals in the U.S., with a global prevalence estimated between 4 to 7 million [8]